Updated on 16 June 2015
OmniComm Systems Inc., a provider of clinical data management technology, announces the selection of the company's Promasys EDC by Integrated Development Associates (IDA), a Tokyo-based Pan Asian drug development company, to run clinical trials in Japan and the Philippines.
Japan represents the second largest pharmaceutical market in the world whereas Philippines is considered to be one of the fastest growing markets.
OmniComm Systems believes that its Promasys system is an important tool that will allow the company to offer its clients with data management and EDC services in a highly reliable and cost efficient manner.
Integrated Development Associates Co. Ltd. (IDA), founded in 2004 and a member of the M3 Group since March 2015, is a Japanese company that provides consulting, CRO and IT driven solutions that enable the optimal development and commercialization of novel biopharmaceutical products for Japan and Asia. IDA's business model enables companies to increase the value of their products through intelligent product development planning, accelerated clinical trial implementation and effective marketing strategies.
"As IDA grows, we see not only the need to integrate Japan into large global studies but also the need to efficiently deliver turn-key Phase I ethnic bridging studies and stand-alone local Japan and Pan Asian clinical trials for clients," said John Winebarger, President and CEO, IDA.